Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Assouline

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 5, 2014
Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trialsTorsten Holm Nielsen, Zuanel Diaz, Rosa Christodoulopoulos, et al.
Blood|October 24, 2024
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapiesLaurie H Sehn, Nancy L Bartlett, Matthew J Matasar, et al.
Blood|February 26, 2025
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLLArnon P Kater, Rosemary Anne Harrup, Thomas J Kipps, et al.
Blood|May 12, 2016
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphomaSarit E Assouline, Torsten Holm Nielsen, Stephen Yu, et al.
Blood|April 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 studyLihua E Budde, Manali Kamdar, Sarit E Assouline, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2019
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin LymphomaIan W Flinn, Carole B Miller, Kirit M Ardeshna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2023
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular LymphomaPier Luigi Zinzani, Jiří Mayer, Christopher R Flowers, et al.
Blood Advances|January 27, 2026
Immunogenicity and Safety of a Third and Subsequent COVID-19 Vaccine Doses in Patients with Plasma Cell DyscrasiasSita Bhella, Gerard Agbayani, Katrina Hueniken, et al.
Cancer|October 1, 2019
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failureEmily C Ayers, Shaoying Li, L Jeffrey Medeiros, et al.
Blood Cancer Discovery|March 9, 2022
Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19Samuel M Rubinstein, Divaya Bhutani, Ryan C Lynch, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 5, 2014
Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trialsTorsten Holm Nielsen, Zuanel Diaz, Rosa Christodoulopoulos, et al.
Blood|October 24, 2024
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapiesLaurie H Sehn, Nancy L Bartlett, Matthew J Matasar, et al.
Blood|February 26, 2025
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLLArnon P Kater, Rosemary Anne Harrup, Thomas J Kipps, et al.
Blood|May 12, 2016
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphomaSarit E Assouline, Torsten Holm Nielsen, Stephen Yu, et al.
Blood|April 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 studyLihua E Budde, Manali Kamdar, Sarit E Assouline, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2019
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin LymphomaIan W Flinn, Carole B Miller, Kirit M Ardeshna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2023
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular LymphomaPier Luigi Zinzani, Jiří Mayer, Christopher R Flowers, et al.
Blood Advances|January 27, 2026
Immunogenicity and Safety of a Third and Subsequent COVID-19 Vaccine Doses in Patients with Plasma Cell DyscrasiasSita Bhella, Gerard Agbayani, Katrina Hueniken, et al.
Cancer|October 1, 2019
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failureEmily C Ayers, Shaoying Li, L Jeffrey Medeiros, et al.
Blood Cancer Discovery|March 9, 2022
Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19Samuel M Rubinstein, Divaya Bhutani, Ryan C Lynch, et al.
Pageof 5